ArticleTranslational cancer research2021
Analysis of the regulation of metastasis-associated lung adenocarcinoma transcript 1 on the biological behavior of breast cancer.
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic and diagnostic values of non-coding RNAs as biomarkers for breast cancer: An umbrella review and pan-cancer analysis.Frontiers in molecular biosciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a class of long non-coding RNA (lncRNA) that has been proved to be closely related to many cancers.
methodsThe relevant research on MALAT1 in cancers published in recent years were collected and integrated. CiteSpace was employed to draw a knowledge map of MALAT1 in breast cancer, to evaluate the research front-burner issues. Then, multiple microarray data sets were searched from online data for meta-analysis to evaluate the relationship between MALAT1 and breast cancer survival rate.
resultsThe results showed that MALAT1 had been widely studied in the proliferation and differentiation of cancer cells, and MALAT1 might regulate breast cancer through the PI3K/AKT/mTOR signaling pathway. In addition, high expression of MALAT1 had a significant correlation with relapse-free survival (HR: 1.51, 95% CI: 0.79-2.29), while there was no significant correlation between MALAT1 expression and overall survival (HR: 1.09, 95% CI: 0.63-1.72).
conclusionsThe expression level of lncRNA MALAT1 was closely related to cancer progression and prognosis of cancer patients. Moreover, the expression of MALAT1 was strongly associated with the survival rate of recurrence-free breast cancer. However, since the present study only adopted the existing literature for visual analysis, subsequent experiments are needed to be done to verify this conclusion. It is hoped that this work could provide a theoretical foundation for promoting the clinical adoption of MALAT1 in the prediction, diagnosis, and treatment of breast cancer, and point out a new direction for the in-depth exploration of the function of MALAT1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.